5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells

Molecular Cancer Therapeutics

Volumn 6, Issue 6, 2007, Pages 1718-1727

  Kiziltepe, Tanyel ^a   Hideshima, Teru ^a   Catley, Laurence ^a   Raje, Noopur ^a   Yasui, Hiroshi ^a   Shiraishi, Norihiko ^a   Okawa, Yutaka ^a   Ikeda, Hiroshi ^a   Vallet, Sonia ^a   Pozzi, Samantha ^a   Ishitsuka, Kenji ^a   Ocio, Enrique M ^a   Chauhan, Dharminder ^a   Anderson, Kenneth C ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOGRAFT INFLAMMATORY FACTOR 1; AZACITIDINE; BORTEZOMIB; CASPASE 8; CASPASE 9; CHECKPOINT KINASE 2; DNA METHYLTRANSFERASE INHIBITOR; DOXORUBICIN; HISTONE H2AX; INTERLEUKIN 6; PROTEIN BAX; PROTEIN MCL 1; PROTEIN NOXA; PROTEIN P53; SOMATOMEDIN C;

APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER CELL CULTURE; CELL GROWTH; CELL SURVIVAL; CYTOTOXICITY; DNA STRAND BREAKAGE; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; HUMAN CELL; IC 50; MITOCHONDRION; MULTIDRUG RESISTANCE; MULTIPLE MYELOMA; OUTCOME ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; BORONIC ACIDS; CELL DIVISION; CELL LINE, TUMOR; CELL SURVIVAL; DNA DAMAGE; DNA, NEOPLASM; DOXORUBICIN; DRUG SYNERGISM; ENZYME INHIBITORS; HUMANS; MULTIPLE MYELOMA; PYRAZINES;

EID: 34250767283     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-07-0010     Document Type: Article

References (77)

1. Issa JP. CpG island methylator phenotype in cancer. Nat Rev Cancer 2004;4:988-93.
2. Laird PW. Cancer epigenetics. Hum Mol Genet 2005;14 Spec No 1: R65-76.
3. Robertson KD. DNA methylation and human disease. Nat Rev Genet 2005;6:597-610.
4. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002;3:415-28.
5. Bird AP. The relationship of DNA methylation to cancer. Cancer Surv 1996;28:87-101.
6. Bender CM, Zingg JM, Jones PA. DNA methylation as a target for drug design. Pharm Res 1998;15:175-87.
7. Taylor SM, Constantinides PA, Jones PA. 5-Azacytidine, DNA methylation, and differentiation. Curr Top Microbiol Immunol 1984;108: 115-27.
8. Jones PA, Taylor SM, Wilson VL. Inhibition of DNA methylation by 5-azacytidine. Recent Results Cancer Res 1983;84:202-11.
9. Claus R, Lubbert M. Epigenetic targets in hematopoietic malignancies. Oncogene 2003;22:6489-96.
10. Bhalla KN. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 2005;23:3971-93.
11. Creusot F, Acs G, Christman JK. Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2′-deoxycytidine. J Biol Chem 1982;257:2041-8.
12. Michalowsky LA, Jones PA. Differential nuclear protein binding to 5-azacytosine - containing DNA as a potential mechanism for 5-aza-2′- deoxycytidine resistance. Mol Cell Biol 1987;7:3076-83.
13. Juttermann R, Li E, Jaenisch R. Toxicity of 5-aza-2′-deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci U S A 1994;91:11797-801.
14. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene 2002;21:5483-95.
15. Szafraniec SI, Stachnik KJ, Skierski JS. New nucleoside analogs in the treatment of hematological disorders. Acta Pol Pharm 2004;61: 223-32.
16. Samlowski WE, Leachman SA, Wade M, et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J Clin Oncol 2005;23: 3897-905.
17. Issa JP. DNA methylation in the treatment of hematologic malignancies. Clin Adv Hematol Oncol 2005;3:684-6.
18. Jackson-Grusby L, Laird PW, Magge SN, Moeller BJ, Jaenisch R. Mutagenicity of 5-aza-2′-deoxycytidine is mediated by the mammalian DNA methyltransferase. Proc Natl Acad Sci U S A 1997;94:4681-5.
19. Davidson S, Crowther P, Radley J, Woodcock D. Cytotoxicity of 5-aza-2′-deoxycytidine in a mammalian cell system. Eur J Cancer 1992;28: 362-8.
20. Karpf AR, Moore BC, Ririe TO, Jones DA. Activation of the p53 DNA damage response pathway after inhibition of DNA methyltransferase by 5-aza-2′-deoxycytidine. Mol Pharmacol 2001;59:751-7.
21. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004;54:8-29.
22. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100:3063-7.
23. Catley L, Tai YT, Chauhan D, Anderson KC. Perspectives for combination therapy to overcome drug-resistant multiple myeloma. Drug Resist Updat 2005;8:205-18.
24. Hideshima T, Richardson P, Anderson KC. Novel therapeutic approaches for multiple myeloma. Immunol Rev 2003;194:164-76.
25. Hazlehurst LA, Damiano JS, Buyuksal I, Pledger WJ, Dalton WS. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000;19:4319-27.
26. Damiano JS, Cress AE, Hazlehurst LA, Shtil AA, Dalton WS. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999;93: 1658-67.
27. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003;348: 2609-17.
28. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001;61: 3071-6.
29. Hideshima T, Chauhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000;96:2943-50.
30. Standal T, Borset M, Lenhoff S, et al. Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor. Blood 2002;100:3925-9.
31. Bataille R, Jourdan M, Zhang XG, Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest 1989;84:2008-11.
32. Hideshima T, Nakamura N, Chauhan D, Anderson KC. Biologic sequelae of interleukin-6 induced PI3-K/Akt signaling in multiple myeloma. Oncogene 2001;20:5991-6000.
33. Klein B, Zhang XG, Lu ZY, Bataille R. Interleukin-6 in human multiple myeloma. Blood 1995;85:863-72.
34. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-30.
35. Freund GG, Kulas DT, Mooney RA. Insulin and IGF-I increase mitogenesis and glucose metabolism in the multiple myeloma cell line, RPMI 8226. J Immunol 1993;151:1811-20.
36. Chauhan D, Kharbanda S, Ogata A, et al. Interleukin-6 inhibits Fas-induced apoptosis and stress-activated protein kinase activation in multiple myeloma cells. Blood 1997;89:227-34.
37. Chauhan D, Pandey P, Hideshima T, et al. SHP2 mediates the protective effect of interleukin-6 against dexamethasone-induced apoptosis in multiple myeloma cells. J Biol Chem 2000;275:27845-50.
38. Mitsiades CS, Mitsiades N, Poulaki V, et al. Activation of NF-κB and up-regulation of intracellular anti-apoptotic proteins via the IGF-I/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene 2002;21:5673-83.
39. Michel B, Flores MJ, Viguera E, et al. Rescue of arrested replication forks by homologous recombination. Proc Natl Acad Sci U S A 2001;98: 8181-8.
40. McGlynn P, Lloyd RG. Recombinational repair and restart of damaged replication forks. Nat Rev Mol Cell Biol 2002;3:859-70.
41. Szostak JW, Orr-Weaver TL, Rothstein RJ, Stahl FW. The double-strand-break repair model for recombination. Cell 1983;33:25-35.
42. Burma S, Chen BP, Murphy M, Kurimasa A, Chen DJ. ATM phosphorylates histone H2AX in response to DNA double-strand breaks. J Biol Chem 2001;276:42462-7.
43. Rothkamm K, Kruger I, Thompson LH, Lobrich M. Pathways of DNA double-strand break repair during the mammalian cell cycle. Mol Cell Biol 2003;23:5706-15.
44. Durocher D, Jackson SP. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? Curr Opin Cell Biol 2001;13:225-31.
45. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis 2006;21:3-9.
46. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004;73:39-85.
47. 2/M transition by p53. Oncogene 2001;20:1803-15.
48. Shieh SY, Ahn J, Tamai K, Taya Y, Prives C. The human homologs of checkpoint kinases Chk1 and Cds1 (Chk2) phosphorylate p53 at multiple DNA damage-inducible sites. Genes Dev 2000;14:289-300.
49. Hirao A, Kong YY, Matsuoka S, et al. DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science 2000;287:1824-7.
50. Jackson SP. Sensing and repairing DNA double-strand breaks. Carcinogenesis 2002;23:687-96.
51. Lobrich M, Jeggo PA. The two edges of the ATM sword: cooperation between repair and checkpoint functions. Radiother Oncol 2005;76:112-8.
52. Kuhne M, Riballo E, Rief N, et al. A double-strand break repair defect in ATM-deficient cells contributes to radiosensitivity. Cancer Res 2004; 64:500-8.
53. 2-M checkpoint activation by histone H2AX and 53BP1. Nat Cell Biol 2002;4:993-7.
54. Roos WP, Kaina B. DNA damage-induced cell death by apoptosis. Trends Mol Med 2006;12:440-50.
55. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer 2003;3:155-68.
56. 2/M checkpoint. EMBO J 2003;22: 6610-20.
57. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004;64:9152-9.
58. Lau A, Swinbank KM, Ahmed PS, et al. Suppression of HIV-1 infection by a small molecule inhibitor of the ATM kinase. Nat Cell Biol 2005;7:493-500.
59. Jazayeri A, Falck J, Lukas C, et al. ATM- and cell cycle-dependent regulation of ATR in response to DNA double-strand breaks. Nat Cell Biol 2006;8:37-45.
60. Pan J, She M, Xu ZX, Sun L, Yeung SC. Farnesyltransferase inhibitors induce DNA damage via reactive oxygen species in human cancer cells. Cancer Res 2005;65:3671-81.
61. Sarkaria JN, Tibbetts RS, Busby EC, et al. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res 1998;58:4375-82.
62. Sarkaria JN, Busby EC, Tibbetts RS, et al. Inhibition of ATM and ATR kinase activities by the radiosensitizing agent, caffeine. Cancer Res 1999; 59:4375-82.
63. Kurz EU, Douglas P, Lees-Miller SP. Doxorubicin activates ATM-dependent phosphorylation of multiple downstream targets in part through the generation of reactive oxygen species. J Biol Chem 2004;279: 53272-81.
64. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
65. Raje N, Kumar S, Hideshima T, et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 2004;104:4188-93.
66. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003;101:2377-80.
67. Hideshima T, Mitsiades C, Akiyama M, et al. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood 2003;101:1530-4.
68. Rudek MA, Zhao M, He P, et al. Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies. J Clin Oncol 2005;23: 3906-11.
69. Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood 2004;104: 607-18.
70. Hideshima T, Anderson KC. Molecular mechanisms of novel therapeutic approaches for multiple myeloma. Nat Rev Cancer 2002;2: 927-37.
71. Rossi JF. Chemoresistance and multiple myeloma: from biological to clinical aspects. Stem Cells 1995;13 Suppl 2:64-71.
72. Fishman-Lobell J, Rudin N, Haber JE. Two alternative pathways of double-strand break repair that are kinetically separable and independently modulated. Mol Cell Biol 1992;12:1292-303.
73. Wichmann A, Jaklevic B, Su TT. Ionizing radiation induces caspase-dependent but Chk2- and p53-independent cell death in Drosophila melanogaster. Proc Natl Acad Sci U S A 2006;103:9952-7.
74. Aliouat-Denis CM, Dendouga N, Van den Wyngaert I, et al. p53-independent regulation of p21Waf1/Cip1 expression and senescence by Chk2. Mol Cancer Res 2005;3:627-34.
75. Pepper CJ, Hambly RM, Fegan CD, Delavault P, Thurston DE. The novel sequence-specific DNA cross-linking agent SJG-136 (NSC 694501) has potent and selective in vitro cytotoxicity in human B-cell chronic lymphocytic leukemia cells with evidence of a p53-independent mechanism of cell kill. Cancer Res 2004;64:6750-5.
76. Tse AN, Schwartz GK. Potentiation of cytotoxicity of topoisomerase in poison by concurrent and sequential treatment with the checkpoint inhibitor UCN-01 involves disparate mechanisms resulting in either p53-independent clonogenic suppression or p53-dependent mitotic catastrophe. Cancer Res 2004;64:6635-44.
77. Teoh G, Tai YT, Urashima M, et al. CD40 activation mediates p53-dependent cell cycle regulation in human multiple myeloma cell lines. Blood 2000;95:1039-46.